Ezogabine, which is known as retigabine in Europe, is a unique anticonvulsant used largely as an adjunctive agent in the treatment of partial seizures.
Liver safety of Ezogabine
Therapy with ezogabine has not been associated with serum aminotransferase elevations, and clinically apparent liver injury from ezogabine has yet to be reported and must be rare, if it occurs at all.
Mechanism of action of Ezogabine
Ezogabine (e zog' a been) is an anticonvulsant with a unique mechanism of action, decreasing excitability and seizure activity by opening voltage-gated potassium channels in the brain. Ezogabine has been shown to be effective both as monotherapy and in combination with other anticonvulsants for partial seizures.
FDA approval information for Ezogabine
Ezogabine was approved for use in the United States in 2011 and current indications are as adjunctive therapy for partial seizures.
Dosage and administration for Ezogabine
Ezogabine is available in tablets of 50, 200, 300 and 400 mg under the brand name Potiga in the United States and Trobalt in Europe and elsewhere. The recommended initial dose in adults is 100 mg three times daily, which can be increased to 200 to 400 mg three times daily. The dose should be increased and tapered gradually.
Side effects of Ezogabine
The most common side effects are dose related and include dizziness, somnolence, impaired concentration, nervousness, headache, fatigue nausea, weakness and tremor. Long term therapy has been associated with urinary retention and blue discoloration of the skin, lips, sclera and retina. Rare, but potentially severe adverse events include psychiatric symptoms such as confusion and hallucination and decrease in visual acuity as a result of retinal pigmentation.